A composition, for example an oil-in-water emulsion, comprising an amphoteric surfactant, alkoxylated cetyl alcohol, a polar dmg and a preservative, wherein the total amount of preservative present in the composition is about 0.2% w/w or less and is not benzyl alcohol and/or triclosan. The drug may be sodium cromoglicate and/or nedocromil sodium. The formulation may be useful in the treatment of skin diseases such as atopic dermatitis.

The present invention concerns a process for preparing a polyphenol-rich extract of dry plant biomass, in particular parts of vines, the extract obtained and its use for antifungal applications, in particular for the prevention and treatment of fungal infections on fruits and plants after harvest, but also for applications related to its antibacterial and antioxidant properties.

The invention relates to novel mTOR inhibitor compounds having the general formula (I), to compositions comprising said mTOR inhibitor compounds, methods for producing same, and the use thereof in compositions as a drug. ##STR00001##

The invention relates to novel mTOR inhibitor compounds having the general formula (I), to compositions comprising said mTOR inhibitor compounds, methods for producing same, and the use thereof in compositions as a drug. ##STR00001##

Embodiments include formulations and methods for topical administration of sugar alcohol to treat a skin condition such as acne. A formulation can include a moisturizer, an emollient, a sugar alcohol and zinc. The sugar alcohol can be erythritol. The erythritol can be administered with zinc chloride. The erythritol and zinc chloride can be formulated at a molar ratio of about 3:1. The methods can also include administration of a therapeutic amount of a second agent such as benzoyl peroxide or a retinoid.

Embodiments include formulations and methods for topical administration of sugar alcohol to treat a skin condition such as acne. A formulation can include a moisturizer, an emollient, a sugar alcohol and zinc. The sugar alcohol can be erythritol. The erythritol can be administered with zinc chloride. The erythritol and zinc chloride can be formulated at a molar ratio of about 3:1. The methods can also include administration of a therapeutic amount of a second agent such as benzoyl peroxide or a retinoid.

The present invention is related to the discovery of new oral dosage formulations and combination therapies for 1-(((2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide, or a pharmaceutically acceptable salt thereof, for treating conditions ameliorated by inhibition of IRAK4.

A method of treating or preventing P. acnes and/or S. aureus infection is described, involving contacting P. acnes and/or S. aureus, or a physiological locus infected or susceptible to infection by P. acnes and/or S. aureus, with at least one of specified bacteriolytic agents. Corresponding pharmaceutical compositions containing such bacteriolytic agents are described, which are useful for treatment or prophylaxis of acne vulgaris and/or S. aureus infection, including methicillin-resistant S. aureus infection.

A method of treating or preventing P. acnes and/or S. aureus infection is described, involving contacting P. acnes and/or S. aureus, or a physiological locus infected or susceptible to infection by P. acnes and/or S. aureus, with at least one of specified bacteriolytic agents. Corresponding pharmaceutical compositions containing such bacteriolytic agents are described, which are useful for treatment or prophylaxis of acne vulgaris and/or S. aureus infection, including methicillin-resistant S. aureus infection.

An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. ##STR00001##
wherein the symbols in the formula are defined below:
A: e.g., Benzene, E: e.g., —CH.sub.2—, G: e.g., a 5-membered aromatic heterocyclic ring, X: e.g., cyclohexane, J: e.g., a 5-membered aromatic heterocyclic ring, Y: e.g., a phenyl group, R.sup.1, R.sup.2, R.sup.3: e.g., a halogen atom, R.sup.4: e.g., a C1-C6 alkyl group, R.sup.5: e.g., a hydrogen atom, R.sup.6a, R.sup.6b, R.sup.6c, R.sup.6d: e.g., a hydrogen atom, R.sup.7: e.g., a hydrogen atom, R.sup.8: e.g., a hydrogen atom, n.sup.1, n.sup.2, n.sup.3: e.g., 1.